B2M and metastatic melanoma: Notably, the fact that B2M defects were predominantly detected in samples taken before treatment from non-responders, as well as in post-progression samples from patients with an initial response to immune checkpoint blockade, suggested that B2M alterations may be involved in both acquired and primary resistance in metastatic melanoma [70].